Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?

摘要

Huddart prospectively investigated changes of health-related quality of life (HRQoL) during and after bladder-sparing therapy (BST) with chemoradiotherapy (CRT) or radiotherapy (RT) alone among participants of BC2001, the largest randomized trial of BST for muscle-invasive bladder cancer (MIBC) ( ), which had found superior loco-regional controls of CRT with fluorouracil plus mitomycin C over those of RT alone ( ). This study demonstrated that although declined at the end of treatment, HRQoL recovered to baseline at 6 months and remained similar to baseline subsequently until 5 years ( ). There was no significant difference in HRQoL between the CRT and RT group at any time point. They concluded that there is no evidence of impairment of HRQoL resulting from the addition of chemotherapy among MIBC patients treated with RT ( ).